Fennec Pharmaceuticals Inc <FENC.OQ> expected to post a loss of 4 cents a share - Earnings Preview
Fennec Pharmaceuticals Inc FENC.OQ FENC.O is expected to show a rise in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The Research Triangle Park North Carolina-based company is expected to report a 31.0% increase in revenue to $9.516 million from $7.26 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fennec Pharmaceuticals Inc is for a loss of 4 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $13.00, about 36.5% above its last closing price of $8.25
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.08 | -0.09 | -0.04 | Beat | 55 |
Dec. 31 2025 | 0.44 | 0.17 | -0.06 | Missed | -136.1 |
Sep. 30 2024 | -0.14 | -0.09 | -0.21 | Missed | -133.3 |
Jun. 30 2024 | -0.11 | -0.03 | -0.20 | Missed | -552.1 |
Mar. 31 2024 | 0.30 | 0.26 | 0.47 | Beat | 79.4 |
Dec. 31 2023 | -0.05 | -0.02 | -0.10 | Missed | -410.2 |
Sep. 30 2023 | -0.12 | -0.12 | -0.07 | Beat | 41.7 |
Jun. 30 2023 | -0.17 | -0.16 | -0.21 | Missed | -34.2 |
This summary was machine generated August 12 at 13:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Warren Buffett Q2 2025 13F Analysis: Betting on UnitedHealth Again After 14 Years
TradingKey - In Q2 2025, the value of Berkshire Hathaway’s investment portfolio declined from $259.8 billion in Q1 to $257.5 billion, a decrease of 0.89%. Analysis indicates that this drop is primarily driven by a net capital outflow of 0.78%. The outflow may be linked to changing market conditions
Applied Materials Q3 Earnings: AI Demand Soars, but Cautious Guidance Triggers After-Hours Selloff
TradingKey - Applied Materials, Inc. (NASDAQ: AMAT) announced its Q3 FY2025 earnings on August 14, 2025, after market close, reporting strong revenue fueled by AI-related semiconductor demand, which beat expectations. However, cautious Q4 guidance, including EPS below analyst estimates.jpg)
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.
